This Chinese herb stands up to cancer
– and a lot more
January 15th, 2017 by Holly Cornish
There’s a venerable Chinese herb, used in Asia for thousands of years, that is now demonstrating profound actions against cancer at a molecular and cellular level in experiments all around the world.
But before I let you in on the impressive details about this plant remedy, I want to point out why there’s so much research these days into learning more about how natural treatments like this one can fight cancer.
A big reason for these studies: In many instances, drug treatments for cancer have hit a wall.
In spite of phenomenal amounts of money spent for research into developing pharmaceuticals that can fight cancer, the results of testing these powerful drugs often turn out to be disappointing. At the same time, the drugs usually have devastating side effects.
But natural compounds like those found in many Chinese herbs are usually much safer and in many instances can work along with the body’s immune system to combat cancer cells in ways that don’t harm other parts of the body.
And that seems to be exactly the case with this traditional Chinese
herb. . .
60 is the New 40
(No longer reserved for the very rich)
Only a few years ago, scientists identified a major cause of aging – and how you can stop it or even reverse it to stay young.
This secret to living a longer, more vibrant life is already sleeping in your cells. You just have to shake it awake!
But like many new discoveries, the technology you need to preserve your cells’ telomeres started out being extremely expensive. It could easily cost $10,000 or more. Only Hollywood moguls and other members of the wealthy one percent could afford it.
Now that’s changed – the breakthrough is affordable. Just imagine. . .
If you’d like to stay young (or just slow down how fast you’re getting old!)…
This may be the most important message you’ve ever received.
The world’s most trusted news outlets are calling it the biggest “against all odds” medical story so far in the 21st century… Everyone raves about it…
…AARP Magazine, CNN, Reader’s Digest, Popular Science, Smithsonian Magazine, BBC News, Oprah Magazine, Reuters, Scientific American, GQ, L.A. Times, The Daily Mail, USA Today, Vanity Fair, The Boston Globe, Shape Magazine, Glamour and The New York Times…
The Chinese have been using the herb astragalus for at least 5,000 years. The emperor Shen Nong, who is recognized as the founder of Chinese herbal medicine, named astragalus as a highly effective medicinal plant in his treatise on botanical medicine, compiled thousands of years ago.
In Chinese, this herb is known as huang-qi, meaning yellow leader (its root has a yellow color). It‘s regarded as an important tonic that functions as an adaptogen – a substance that helps the body adapt and cope with a wide variety of stresses, toxins and even emotional difficulties.
People have long used astragalus to treat skin wounds. It’s also taken to boost immunity and help the body fight off viruses like the common cold. It may help control blood sugar and lower the risk of diabetes and heart problems. It may even ease hay fever and allergies.1
But along with these types of traditional uses, medical researchers are discovering that its molecular behavior in the body when it encounters cancer cells may soon make it an especially valuable weapon in our medical arsenal.
Scars and cancer
In one study, when researchers in Asia took a look at how astragalus might help stop liver cancer from forming, they focused on how the herb can prevent or reverse liver fibrosis – a scarring process among liver cells that can be a first step in the progression to cancer.
Fibrosis in the liver can result from a chronic liver disease like hepatitis or just from putting on extra pounds – as many Americans do these days. These burdens on the liver cause inflammation that leads to scarring from an excessive build-up of harmful forms of collagen – structural tissue that, under normal circumstances, is a good thing because it strengthens skin, bones and connective tissue.
As the researchers point out, in mainstream Western medicine, “Current therapies target(ed) at arresting or reversing liver fibrosis are largely ineffective and some have unacceptable side effects in long-term therapy.”2
In this research, the scientists found that bioflavonoids in astragalus (beneficial phytochemicals that give astragalus its color) could help liver cells fight back against fibrosis with their own built-in antioxidant defenses. Their lab analysis demonstrated that the bioflavonoids boosted levels of superoxide dismutase, one of the body’s fundamental antioxidant enzymes.
Long-time readers of this newsletter know about the value of superoxide dismutase (SOD – see Issue #375.) The increased presence of SOD is important for preventing collagen from taking the forms that can develop into scar tissue in the liver. The enzyme may actually be able to reverse the scarring process.3
An analysis of other ways astragalus can help reverse fibrosis shows that it cuts back on oxidative stress in the liver by reducing release of a substance called malondialdehyde. Malondialdehyde is a chemical known to be involved in the free radical destruction of liver cells. It can react with proteins in the liver to accelerate the growth of scar tissue.
Repairs your digestive tract
Astragalus has also been shown to repair damage to the stomach and digestive tract that otherwise allows cancer to spread.
One test in China centered on the relationship between the mesothelial cells that line the stomach and cancer’s slash-and-burn tactics that kill these protective cells.
Mesothelial cells have been called “pavement” cells because they form a relatively solid, slippery surface in the stomach that doesn’t allow invasive attack into the more vulnerable cells that grow behind or beneath the lining.
But when cancer cells enter the stomach as they attempt to spread – metastasize – throughout the body, they release inflammatory chemicals that cause the mesothelial cells to die off, which opens up avenues for tumors to take hold and expand.
Once the mesothelial lining has been stripped off, cancer cells rapidly implant themselves in the exposed cells and begin growing new stomach tumors.
Astragalus to the rescue: The researchers found the herb could help the mesothelial cells better defend themselves against the predatory cancer cells. They apparently do this by stimulating the release of proteins that keep mitochondria (energy-producing organelles) in the protective cells functioning better.4
The scientists who conducted this study point out that research needs to continue into how astragalus “can thus be used in treatment of gastric cancer.”
An ally against colon cancer
Further down the digestive tract, other studies have shown that natural compounds in astragalus can be used to deter colon cancer.
An analysis of the herb’s benefits in the colon shows that natural chemicals in astragalus can stop the spread of cancer on the walls of the colon by gumming up the inner workings of the cancer cells when they try to replicate themselves.5
These researchers also urge mainstream doctors to develop astragalus as a natural treatment for cancer, noting that it is much safer than chemotherapeutic drugs: “In contrast to orthodox chemotherapy using cytotoxic drugs, the use of this herbal extract imposes less toxicity while its anti-tumor effects could remain.”
Even when cancer patients have been treated with chemotherapy or radiation, astragalus has been shown to help offset the powerful side effects of these pharmaceuticals – restoring immune function when immune cells have been destroyed6 and protecting heart tissue from the harm that chemotherapy can wreak.7
I’m hoping that some of the Chinese research finds its way into the hidebound, drug-obsessed American medical system. The scourge of cancer is too widespread to allow wonderful botanicals like astragalus to be neglected.
Our sister company, Green Valley Natural Solutions, offers a supplement called Genesis that contains a clinical dose of the best form of astragalus we could find, called cycloastragenol. The Genesis formula is designed to boost healthy people – it’s not a cancer treatment. But if I do say so myself, it’s a remarkable collection of super-nutrients like alpha-lipoic acid, coenzyme Q10, pterostilbene and grapeseed extract (if you already take these, you won’t need the other brands, you’ll get all you need from Genesis.) Click here for the full story.
Chemotherapy for Late-Stage Cancer Patients
Is Just Plain Unethical
Doctors and patients should question whether a particular test or treatment is really necessary.
No need to take my word for it. This is the advice of the Academy of Medical Royal Colleges (AMRC), A UK organization that represents 22 medical colleges.
In October 2016, they listed 40 routine medical procedures that have little or no effect or benefit for the patient. One of these was chemotherapy for patients with advanced or late-stage cancer.
It’s time to just state it plainly: Chemotherapy for late-stage cancer patients is an immoral practice. Medical and government authorities, if they have any integrity at all, should put a stop to it.
The AMRC said that chemotherapy is toxic, can cause great harm, may fail to achieve a meaningful response, and raises false hope.
The following month, Peter H Wise, a retired consultant oncologist, went further. Writing in the British Medical Journal, he questioned, among other practices, the ethics of how the government approves very expensive drugs that yield only small survival benefits in metastatic cancer.
Let’s take a quick look at the arguments he put forward. . .
No more waiting months and months.
First big breakthrough in
A landmark clinical study conducted by Italian doctors has revealed a little known amino acid that naturally skyrockets a man’s testosterone by as much as 42%. And fast, too—in just 12 days.
The experts agree: Testosterone is a “lifesaver” for you, especially if you’re nearing or over age 50.
Heightened levels of testosterone surging through your body can mean:
The problem is, most every low testosterone solution
If history is any indication, the government may soon ban many legitimate natural testosterone boosters by lumping them in with steroids and unnatural hormones.
Yet at this writing, this amazing amino acid is available to you. Perfectly legal. Over the counter. Clinically tested on men. And all natural.
To find out the full story of this remarkable testosterone-boosting health breakthrough for men, go here now.
Chemotherapy increases survival by 3 months
To be absolutely fair, there have been improvements in five-year survival rates, with an increase from 49% in 1975 to 68% in 2010. But Dr. Wise asks “how much of the [19%] improvement….can we attribute to drugs?”
In 2004, doctors for the Northern Sydney Cancer Centre in Australia reviewed five-year survival benefits attributable to cytotoxic chemotherapy – and nothing else — in malignancies of Americans and Australians. All the subjects of the study were adults.
Of 155,000 Americans included, important effects were seen in some cancers: testicular (37.7%), Hodgkin’s disease (40.3%), cervix (12%), Non-Hodgkin’s lymphoma (10.5%) and ovarian (8.9%). But these represented just 8.3% of all cases.
The remaining 91.7% included the most common cancers, such as breast, colorectum, lung and prostate. For people with advanced cases of these cancers, survival rates were extremely low.
Of all cancers included in the review, drug therapy increased five-year survival by only 2.1%, which equates to an average lifespan increase of only three months.
Italian researchers writing in the British Journal of Cancer found that 14 consecutive new drugs approved by the European Medicines Agency (EMA) for adult solid cancers improved overall survival by an average of 1.2 months. (A solid cancer is one that affects an organ such as breast, liver or prostate, as distinguished from a bodily fluid like blood or lymph. Most cancers are solid.)
Of 48 new drugs approved by the FDA between 2002 and 2014, the average overall survival benefit was 2.1 months.
It would seem that little of the 19% improvement in five-year survival is due to chemotherapy.
Drug trials: Do patients understand
what they’re signing up to?
There are also ethical questions regarding participation in drug trials.
Studies suggest patients may feel pressured to enroll, believing this to be their only option. Although they take part in the hope of personally benefiting, this is a rare outcome. Most patients don’t realize the trial is for the betterment of other patients in the future.
This caveat is personal for me. One of my best friends, who had leukemia, died in reaction to an experimental stem cell treatment. He had been doing well before volunteering to be a guinea pig (leukemia is pretty treatable). He left behind a wife and ten-year-old whose lives were devastated by the loss.
I have a small bit of personal experience with drug trials. I participated in one as a college student, many decades ago, because, frankly, I needed the money and they were paying. When I had a bad reaction and withdrew from the trial, the doctor who was running the project severely criticized me.
Even if there is a positive outcome from a chemo drug trial, this doesn’t ensure the results will be replicated outside of the trial setting. Quite often the result of a trial is just a few extra weeks of life compared to the average for patients with the same disease who are not treated with the experimental drug.
Such results are NOT significant. And the drugs, if approved, are then marketed as a “new breakthrough’ – extremely expensive, of course. Oncologists promptly start treating their patients with the new drug when there are older, less expensive chemo drugs available that work just as well.
Only three percent of cancer patients take part in trials. In the other
97%, staffing and procedures can be quite different with no guarantee of similar outcomes.
The value of such trials is also questionable.
Previous university-based trial procedures have been replaced by outsourcing to commercial contract research organizations (CROs) responsible only to the company that hired them. These are increasingly conducted in low/middle income countries, a practice called offshoring.
A study which looked at the effect of outsourcing described “the extreme lack of transparency of CROs in particular and the pharmaceutical sector in general.” The authors concluded that many of these trials “place patients at ethical risk.”
Speeding up drug approval
The most meaningful measure of a drug’s worth is overall survival – from the time the drug is first taken until the patient’s death.
However, in the pressure to speed up the drug approval process, many trials look at other measures of “success” – so-called “surrogate endpoints” — such as early shrinkage of the tumor, the overall response to the drug, and progression-free survival – the time that passes without the tumor becoming larger or spreading.
All these are measured by imaging, but in the vast majority of cases, they don’t have much connection to overall survival. It’s depressing news – even for patients using some alternative treatments – but tumor shrinkage doesn’t necessarily mean you’re getting better. Tumor size is a symptom; effective cancer treatment tackles the root causes such as toxins, high blood sugar, and a weak immune system.
The “surrogate endpoints” like tumor shrinkage are also used by the FDA and EMA for accelerated approval. Yet 45% of drugs given accelerated approval by the FDA never go on to win full approval because follow-up trials did not confirm they added time to the patients’ lives.
The risks of approving ineffective or unsafe drugs was further compounded in 2012 when the FDA introduced its “breakthrough” category of drugs. For these, preliminary evidence indicates the drug may show substantial improvement over existing drugs.
I can understand that late-stage patients may be willing to roll the dice on an experimental drug. There’s an active, noisy political movement demanding access to drugs that aren’t yet FDA-approved.
But what doctors should do is explain to patients that these new drugs will extend life only a few weeks, if at all, and that the patient should consider gentle, effective alternative therapies. I can’t guarantee results, but I’ve met plenty of late-stage patients who made amazing recoveries when they turned to alternatives.
In addition to overall survival, oncologists consider quality of life an important factor in cancer care, yet improvements in quality of life from chemotherapy are tiny, and even where they do exist, they don’t last long.
In my opinion, the words “chemotherapy” and “quality of life” don’t even belong in the same sentence.
The ethical principles of fairness and equity must be questioned when drugs are given such a low threshold for approval, for the treatment of types of tumors that don’t respond well — and with benefit to so few patients.
In the United States, massive resources – many, many billions of dollars – are spent on chemotherapy for late-stage cancer patients. The money is almost entirely wasted and could be better spent elsewhere in our bankrupt, overburdened medical system. Money is literally being taken from babies to fund this out-of-control cancer industry.
The fast-tracking of chemotherapy drugs may benefit a tiny number of patients, about the same way the lottery benefits a few winners. Some people do recover or see a substantial life extension, not just a few weeks. But the real winners are the drug companies with 22% profit margins on national cancer drug sales of $50 billion.
Another doubtful ethical practice is the so called revolving door, whereby the drug industry hires people who used to work for the regulatory agencies. “Thus the regulator risks being regulated by the industry that it has been appointed to regulate,” says Peter Wise.
Another winner may be the oncologist. A study published in the Journal of Clinical Oncology found that a considerable number of oncologists, mainly the independent ones who work for themselves rather than a hospital, enjoy an increase in their income when they administer chemotherapy.
Patients expect too much
Cancer treatment represents a considerable financial burden even for patients with insurance. In fact, it’s a major cause of personal bankruptcy. Yet consent forms are often neither issued or signed.
Few patients are fully informed that four out of five cancer drugs bring on side effects – nearly all of which are serious. They also don’t understand that the treatment itself can kill them.
Not being aware of the dismal treatment outcomes – much less the nontoxic, natural alternatives — patients hardly ever question the oncologist’s proposal for chemotherapy. An ethical system is one where patients are empowered. They are given accurate and impartial information so that consent is genuinely informed.
In a study published in the New England Journal of Medicine, three-quarters of terminally ill patients believed chemotherapy could cure them.
How can people make an intelligent decision when they believe such nonsense?
The same article reports that only one late-stage patient out of four is told that supportive care is an option. Supportive care can enhance the quality of life and even extend life. It’s all but certain that another round of chemo is not going to extend such a patient’s life. It’s going to make what life they have left completely miserable.
If you or someone you love is faced with this choice, why not be comfortable instead, and even throw in some harmless alternatives — like immune-supporting supplements and natural anti-inflammatories, not to mention getting off the sugar and other refined carbs? I repeat, these simple, safe steps often lead to dramatic turnarounds.
Dr Wise concludes that “aggressively targeting the less than ethical actions of stakeholders in the heavily veiled medical-industrial complex may be the only way forward: current market driven rather than health driven priorities and practices do not benefit cancer patients.”